Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Change in Accured Expenses of $43372.0 for Q1 2026, down 94.79% year-over-year from $833219.0 in Q1 2025, and down 89.79% quarter-over-quarter from $424899.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Change in Accured Expenses data on file, last reported at $43372.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $43372.0, down 94.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $611405.0 (down 39.2% YoY), and the FY2025 annual result was $1.4 million, up 233.57% from the prior year.
- Change in Accured Expenses slipped to $43372.0 in Q1 2026 per IKT's latest filing, from $424899.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $858240.0 in Q1 2022 and troughed at -$1.3 million in Q3 2022.
- A 5-year average of $82876.1 and a median of $132394.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 15605.69% in 2022, then tumbled 273.47% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $132394.0 in 2022, then surged by 203.44% to $401740.0 in 2023, then climbed by 29.1% to $518656.0 in 2024, then decreased by 18.08% to $424899.0 in 2025, then tumbled by 89.79% to $43372.0 in 2026.
- Business Quant data shows IKT's Change in Accured Expenses at $43372.0 in Q1 2026, $424899.0 in Q4 2025, and $718197.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | 43,372.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,372.00 |
| Mar 31, 2026 | 43,372.00 |
| Dec 31, 2025 | 424,899.00 |
| Dec 31, 2025 | 424,899.00 |
| Sep 30, 2025 | 718,197.00 |
| Sep 30, 2025 | 718,197.00 |
| Jun 30, 2025 | -575,063.00 |
| Jun 30, 2025 | -575,063.00 |
| Mar 31, 2025 | 833,219.00 |
| Mar 31, 2025 | 833,219.00 |
| Dec 31, 2024 | 518,656.00 |
| Dec 31, 2024 | 518,656.00 |
| Sep 30, 2024 | 126,849.00 |
| Sep 30, 2024 | 126,849.00 |
| Jun 30, 2024 | -473,064.00 |
| Jun 30, 2024 | -473,064.00 |
| Mar 31, 2024 | 247,634.00 |
| Mar 31, 2024 | 247,634.00 |
| Dec 31, 2023 | 401,740.00 |
| Dec 31, 2023 | 401,740.00 |